HORSHAM, PA — Biocoat Incorporated, a leading player in the biomaterials sector, has announced the appointment of Scott D’Amour as its new Chief Financial Officer. D’Amour steps into the role previously held by Steve Bell, who will retire in November 2023 after serving since January 2019.
D’Amour brings to Biocoat over 25 years of experience in financial leadership roles across various industries, including life sciences, medical technology, and technology. His impressive career portfolio includes tenures at Leidos, Berkshire Grey, Medtronic, HeartWare, Biotage, Bioprocessors, and Applied Biosystems. D’Amour holds an MBA and a Master of Science in Finance from Boston College’s Carroll Graduate School of Management, and a Bachelor of Science in Management from the University of Massachusetts Lowell.
Jim Moran, President and CEO of Biocoat, expressed his appreciation for the outgoing CFO and welcomed D’Amour into the fold. “Steve has led all financial dealings for two different private equity transactions and was an integral part of Biocoat’s growth over the last five years. We cannot thank Steve enough for his dedication and expertise,” said Moran. “We are excited to put Scott’s broad experience into action as we further expand Biocoat’s full-service offering in the medical device industry.”
D’Amour also expressed enthusiasm about his new role. “I am excited to join Biocoat at a time when the company is experiencing growth and is focused on expanding into the biomaterials market. I look forward to joining an amazing team that is dedicated to the continued growth of the organization,” he said.
The transition marks a key moment in Biocoat’s journey as it continues to expand its reach in the biomaterials market, with D’Amour’s expertise set to play a significant role in this phase.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.